| Literature DB >> 31002437 |
Seppe Vander Beken1, Juliane C de Vries1, Barbara Meier-Schiesser1, Patrick Meyer1, Dongsheng Jiang1, Anca Sindrilaru1, Filipa F Ferreira1, Adelheid Hainzl1, Susanne Schatz1, Jana Muschhammer1, Natalie J Scheurmann1, Panagiotis Kampilafkos1, Andreas M Seitz2, Lutz Dürselen2, Anita Ignatius2, Mark A Kluth3,4, Christoph Ganss3,4, Meinhard Wlaschek1, Karmveer Singh1, Pallab Maity1, Natasha Y Frank5,6,7, Markus H Frank5,8,9,10, Karin Scharffetter-Kochanek1.
Abstract
In this study, we report the beneficial effects of a newly identified dermal cell subpopulation expressing the ATP-binding cassette subfamily B member 5 (ABCB5) for the therapy of nonhealing wounds. Local administration of dermal ABCB5+ -derived mesenchymal stem cells (MSCs) attenuated macrophage-dominated inflammation and thereby accelerated healing of full-thickness excisional wounds in the iron-overload mouse model mimicking the nonhealing state of human venous leg ulcers. The observed beneficial effects were due to interleukin-1 receptor antagonist (IL-1RA) secreted by ABCB5+ -derived MSCs, which dampened inflammation and shifted the prevalence of unrestrained proinflammatory M1 macrophages toward repair promoting anti-inflammatory M2 macrophages at the wound site. The beneficial anti-inflammatory effect of IL-1RA released from ABCB5+ -derived MSCs on human wound macrophages was conserved in humanized NOD-scid IL2rγ null mice. In conclusion, human dermal ABCB5+ cells represent a novel, easily accessible, and marker-enriched source of MSCs, which holds substantial promise to successfully treat chronic nonhealing wounds in humans. Stem Cells 2019;37:1057-1074.Entities:
Keywords: Cell surface markers; Clinical translation; Mesenchymal stem cells; Tissue regeneration; Tissue-specific stem cells; Xenotransplantation
Mesh:
Substances:
Year: 2019 PMID: 31002437 PMCID: PMC6663647 DOI: 10.1002/stem.3022
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277